B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. - Wikidata - wikimedia - TriplyDB

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q35153156

about

Current challenges and novel treatment strategies in double hit lymphomas MYC-driven aggressive B-cell lymphomas: biology, entity, differential diagnosis and clinical management Next-generation prognostic assessment for diffuse large B-cell lymphoma Biology of double-hit B-cell lymphomas Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system The copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphoma EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas Mortality and survival patterns of childhood lymphomas: geographic and age-specific patterns in Southern-Eastern European and SEER/US registration data.Role of MYC in B Cell Lymphomagenesis.New developments in the pathology of malignant lymphoma: a review of the literature published from October 2009 to January 2010 Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies.Automatic lymphoma classification with sentence subgraph mining from pathology reports.Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.Spinal cord compression by B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma in a patient seropositive for human immunodeficiency virus: a case report Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Complete response to induction therapy in patients with Myc-positive and double-hit non-Hodgkin lymphoma is associated with prolonged progression-free survival The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.The histological classification of diffuse large B-cell lymphomas Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?Management of Patients with MYC-Altered Lymphomas.Genetic lesions in diffuse large B-cell lymphomas Defining causative factors contributing in the activation of hedgehog signaling in diffuse large B-cell lymphoma.Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.Cutaneous presentation of Double Hit Lymphoma: A Case Report With Review of the Literature.MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Pr Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results.MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.Immunohistochemical evaluation of MYC expression in mantle cell lymphoma.Prognostic impact of history of follicular lymphoma, induction regimen and stem cell transplant in patients with MYC/BCL2 double hit lymphoma Double-hit lymphomas: clinical, morphological, immunohistochemical and cytogenetic study in a series of Brazilian patients with high-grade non-Hodgkin lymphoma Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas: A Retrospective Cohort Study

P2860

Q26770385-561D307A-4F6A-4D74-82DF-D30005FF5D31 Q26785379-A6339475-8621-4583-8BE1-5D27822ACF61 Q26796428-384A7953-72BB-4AA3-B8FE-A4BD9F4F1470 Q26825581-2AD3EC3B-9FDA-4B2E-AE1F-A277D33382A1 Q27304386-6771C41B-8A5A-42BC-81F4-18C2C9C0D750 Q28256567-A19FAC58-DBA5-4049-A374-6DCC2F6DD13B Q28262278-0D100C0E-94E6-43BF-8275-E90ADC168888 Q28389285-F746F8E9-7B55-484B-A0AB-F6DBEB459607 Q28741454-B7485989-5978-4621-BDE3-EAC9D58C71F6 Q31131542-A1E72EFF-AE6E-4A2F-8ED2-1D04C58D5B4D Q33608499-46392080-7838-4AF2-8D63-B900FABD5083 Q33906881-AB86A850-DCE7-402E-851D-2C141E63D14B Q33980435-EF38C63B-E10E-4786-88F1-D374FF2C0CEC Q34101867-C4766A94-B194-43D4-8430-A62323415EFD Q34257135-B008B260-6546-443E-AFDA-F9E64AD085B4 Q34314178-2CB6270D-9DC7-406F-B195-97C410A19233 Q34335894-8AF7CC4A-37FA-427B-97A2-E3969EA2A775 Q34882773-9BF6595D-55BC-494A-8815-B67CDDD02887 Q34918948-568EDDE6-E75D-44D5-B618-4100B7338A73 Q35029409-875645CA-5F63-449C-BC75-B45A13C42DD1 Q35030096-F0A512A7-DFB7-44FF-9C12-FDC61D2403A3 Q35218051-861F1921-2974-4611-B086-587486EC6971 Q35384536-3F575FC7-DEF5-4BE7-ABA7-5FE796012B71 Q35960027-4EC84CD9-A330-45AF-A2E0-6A2E7BFD6A46 Q35974341-F24D76FB-0274-4A6D-8EDC-F9BFD2D42640 Q36173809-A5B2A68A-C9C3-4C90-BF85-F45F62E7AEEA Q36192439-853BDD4D-A7DF-4CA9-A8E6-2308174187B4 Q36267666-628E703D-0BA0-48AE-BE4F-730B3F347B60 Q36280547-0A909136-978B-45AA-91B5-AB3FB9E218E1 Q36602853-1D49FBC1-2135-4650-A5D2-623E59C0C9E8 Q36771814-8B44F831-7C90-4E43-958D-ABAB485AE877 Q36799405-870A43CB-E97C-4934-828B-2C21F956F9A4 Q37006876-14BD37AD-8FBF-42D6-ACF2-7F040CEB944A Q37109671-BD8CB44A-B094-4676-8D5C-2D27BC3E44C0 Q37195045-7738B908-F81A-4745-BC3F-1FE521802076 Q37212700-2BF1880A-1635-424F-88A5-89EEC6F63975 Q37412155-BC06DA79-35DB-44D4-9AA6-148CE1B058B1 Q37437423-63576E8D-1720-4B73-B90B-86B404C7EED9 Q37569804-2BF30291-06C8-4805-A967-1568FEE6987F Q37624237-E7AFA83F-FBA4-4CCD-B395-A0A49110CF56

P2860

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

http://www.wikidata.org/entity/Q35153156

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

B-cell lymphomas with concurre ...... diffuse large B-cell lymphoma.

@ast

B-cell lymphomas with concurre ...... diffuse large B-cell lymphoma.

@en

type

label

B-cell lymphomas with concurre ...... diffuse large B-cell lymphoma.

@ast

B-cell lymphomas with concurre ...... diffuse large B-cell lymphoma.

@en

prefLabel

B-cell lymphomas with concurre ...... diffuse large B-cell lymphoma.

@ast

B-cell lymphomas with concurre ...... diffuse large B-cell lymphoma.

@en

P1433

Q35153156-9EE12B99-BCEB-4AE7-B9BE-D0F14564D4EB

P1476

Q35153156-A538B958-6819-42FB-82B6-2624AE3E42B0

P2093

Q35153156-0039687B-C950-4CB7-9A02-25491C4EFF76

Q35153156-03D71A64-040D-4854-ACE6-41F74E440D73

Q35153156-1CCEF0F8-1410-44F1-8DFD-F0E37295C61C

Q35153156-31E2348D-1EB6-41ED-82E4-359303E5429E

Q35153156-32C59A1A-3231-43D9-AD6F-CA54C1C96325

Q35153156-3445F11A-FCEB-4DA1-BDA4-2230FCB45977

Q35153156-36960030-1F53-4AF0-BD71-63DDA2E002B0

Q35153156-44D592E8-F827-4719-912E-A9320EB87FAF

Q35153156-5AC0B71C-C2AB-410D-A8AE-E038A420D9DA

Q35153156-5E92BFD5-8108-46C8-98CB-3A733D37A879

P2860

Q35153156-1EE37001-ED16-4298-A60C-33C85E791228

Q35153156-27C8B9B2-10EE-464A-AF19-D2013457518A

Q35153156-2C1A94F8-A687-4BC0-9136-AF31321A2041

Q35153156-325408EF-ECBB-4E11-9DA8-14F07B32C3AC

Q35153156-3896BC6D-950B-4876-AC13-C83C88A456B4

Q35153156-39B8856B-AFB1-4261-9BAE-17019E6ABF2A

Q35153156-3CECE795-89DE-404C-AF70-B2BF4DF93CCB

Q35153156-430EB413-3A26-45E4-8C85-3190B94AA317

Q35153156-4D92F5C0-8531-463D-9D93-24967D87378D

Q35153156-5BC53C73-A5D2-42BE-BDDA-91120D997430

P304

Q35153156-D3288E4F-3357-452A-95A5-19F2B84EE457

P31

Q35153156-03BA813E-263F-45A5-A197-5AEDA71B3A91

P356

Q35153156-0B7FD4C5-1667-494B-9049-2705BC923B58

P407

Q35153156-A5D4EAFD-3D23-4AC4-9138-173DEC331807

P433

Q35153156-72C1DEE7-1626-4688-BB4E-6F819CCFEC04

P478

Q35153156-A3AD0BC3-6BEB-4AD6-AF3B-2C8711A64783

P577

Q35153156-28EC41EE-ED91-4B05-A5CE-E4D7A2F19A25

P5875

Q35153156-10815C5B-D05C-4555-BCB8-5E7C4D5C2F24

P698

Q35153156-530484BF-27A2-4BBA-89C9-8AC19E1A19C1

P921

Q35153156-2B0D0D11-EF95-4DE8-ABA7-148CE6571749

P932

Q35153156-E5CB0FE2-DF36-4E26-B88E-27ADCB8C71BD

P356

PAS.0B013E3181CD3AEB

P1433

The American Journal of Surgical Pathology

P1476

B-cell lymphomas with concurre ...... diffuse large B-cell lymphoma.

@en

P2093

Adam M Ackerman

http://www.w3.org/2001/XMLSchema#string

Alfred I Lee

http://www.w3.org/2001/XMLSchema#string

Aliyah R Sohani

http://www.w3.org/2001/XMLSchema#string

Christiana E Toomey

http://www.w3.org/2001/XMLSchema#string

Ephraim P Hochberg

http://www.w3.org/2001/XMLSchema#string

Hang Lee

http://www.w3.org/2001/XMLSchema#string

Jeremy S Abramson

http://www.w3.org/2001/XMLSchema#string

Jessie J Hsu

http://www.w3.org/2001/XMLSchema#string

Judith A Ferry

http://www.w3.org/2001/XMLSchema#string

Lawrence R Zukerberg

http://www.w3.org/2001/XMLSchema#string

P2860

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma.

Atypical Burkitt lymphoma arising from follicular lymphoma: demonstration by polymerase chain reaction following laser capture microdissection and by fluorescence in situ hybridization on paraffin-embedded tissue sections.

Chromosomal analyses of 52 cases of follicular lymphoma with t(14;18), including blastic/blastoid variant.

Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas.

Mature B-cell acute lymphoblastic leukemia with associated translocations (14;18)(q32;q21) and (8;9)(q24;p13). A Burkitt variant?

Follicular lymphoma with a burkitt translocation--predictor of an aggressive clinical course: a case report and review of the literature.

Follicular lymphoma with trisomy 18 exhibiting loss of BCL-2 expression on transformation to a large cell lymphoma.

Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.

P304

327-340

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/PAS.0B013E3181CD3AEB

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41191826

http://www.w3.org/2001/XMLSchema#string

P698

20118770

http://www.w3.org/2001/XMLSchema#string

P921

Burkitt lymphoma

P932

3152212

http://www.w3.org/2001/XMLSchema#string